Zynex Inc
NASDAQ:ZYXI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.19
13.74
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Zynex Inc
Zynex Inc
Accounts Receivables
Zynex Inc
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zynex Inc
NASDAQ:ZYXI
|
Accounts Receivables
$21.6m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
38%
|
CAGR 10-Years
17%
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Accounts Receivables
$3B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Accounts Receivables
$2.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
7%
|
CAGR 10-Years
7%
|
|
|
Stryker Corp
NYSE:SYK
|
Accounts Receivables
$3.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Accounts Receivables
$6.9B
|
CAGR 3-Years
2%
|
CAGR 5-Years
5%
|
CAGR 10-Years
7%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Accounts Receivables
$1.2B
|
CAGR 3-Years
18%
|
CAGR 5-Years
13%
|
CAGR 10-Years
16%
|
|
Zynex Inc
Glance View
Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. The company is headquartered in Englewood, Colorado and currently employs 774 full-time employees. The company went IPO on 2002-11-27. The Company’s devices are intended for pain management to reduce reliance on drugs and medications and provide rehabilitation and through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current (IFC), neuromuscular electrical stimulation (NMES) and transcutaneous electrical nerve stimulation (TENS). The Company’s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, and E-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Distributed Complementary, which includes Comfortrac/Saunders, JetStream, Knee Braces and LSO Back Braces, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter. CM-1500 is a Zynex fluid monitoring system.
See Also
What is Zynex Inc's Accounts Receivables?
Accounts Receivables
21.6m
USD
Based on the financial report for Sep 30, 2024, Zynex Inc's Accounts Receivables amounts to 21.6m USD.
What is Zynex Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 10Y
17%
Over the last year, the Accounts Receivables growth was -35%. The average annual Accounts Receivables growth rates for Zynex Inc have been -4% over the past three years , 38% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet
